NVAX

#2093
Novavax, Inc. - Common Stock
11.0 9 USD
+7.46%
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
10.89
11.19
Year Range
6.13
11.97
Daily Change
+7.46%
Monthly Change
+38.45%
6 month change
+61.90%
Year Change
+56.64%
Previous Close
10.3 2
Open
10.9 4
Low
10.8 9
High
11.1 9
Volume
1 399
Open full chart Full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 1.82 B
  • Employee 749
  • Founded 1987
  • CEO John C. Jacobs
  • Website www.novavax.com
  • Headquarter Delaware, United States
  • FIGI BBG000NVSBL7
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-19.85
Price to sales ratio
2.33

Novavax, Inc. - Common Stock

Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus, avian flu, shingles, Clostridioides difficile, and malaria. Novavax develops proprietary immune-stimulating saponin-based immunologic adjuvants at a wholly owned Swedish subsidiary, Novavax AB. One of these, Matrix-M, is used in the Novavax COVID-19 vaccine.

News